These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35722762)

  • 1. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.
    Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E
    Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates.
    Marco A; Roget M; Cervantes M; Forné M; Planella R; Miquel M; Ortiz J; Navarro M; Gallego C; Vergara M;
    J Viral Hepat; 2018 Nov; 25(11):1280-1286. PubMed ID: 29851225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C Virus Elimination Program among Prison Inmates, Israel.
    Eisen L; Mor Z; Madar M; Rabinovitch R; Dadon Y; Sheffer R; Kaliner E; Goldstein L
    Emerg Infect Dis; 2023 Nov; 29(11):2358-2361. PubMed ID: 37877627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Hepatitis C Cascade of Care in Prisoners-Is There Still Some Work to Do? Analysis of Two Large Penitentiaries in Northern Italy.
    Cambianica A; Marchese V; Pennati F; Faustinelli A; Migliorati M; Roda F; Spinetti A; Zaltron S; Fiorentini S; Caruso A; Quiros-Roldan E; Castelli F; Focà E
    Int J Environ Res Public Health; 2024 Jan; 21(1):. PubMed ID: 38248566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
    Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
    Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
    Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
    Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
    J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
    Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
    J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients.
    Cooper CL; Hatashita H; Corsi DJ; Parmar P; Corrin R; Garber G
    Ann Hepatol; 2017 November-December,; 16(6):874-880. PubMed ID: 29055923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
    Marco A; Antón JJ; Trujols J; Saíz de la Hoya P; de Juan J; Faraco I; Caylà JA;
    BMC Infect Dis; 2015 Aug; 15():355. PubMed ID: 26286450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
    Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
    Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients.
    Wong YJ; Thurairajah PH; Kumar R; Fock KM; Law NM; Chong SY; Manejero FG; Ang TL; Teo EK; Tan J
    Clin Mol Hepatol; 2021 Jul; 27(3):474-485. PubMed ID: 33601868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of telemedicine to hepatitis C elimination in a correctional facility.
    Jiménez Galán G; Alia Alia C; Vegue González M; García Berriguete RMª; Fernández González F; Fernández Rodríguez CM; González Fernández M; Gutiérrez García ML; Losa JE; Velasco M; Moreno L; Hervás R; Delgado-Iribarren A; Palacios García-Cervigón G
    Rev Esp Enferm Dig; 2019 Jul; 111(7):550-555. PubMed ID: 31215210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
    Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of telehealth to increase treatment access for prisoners with chronic hepatitis C.
    Halder A; Li VG; Sebastian M; Nazareth S; Tuma R; Cheng W; Doyle A
    Intern Med J; 2021 Aug; 51(8):1344-1347. PubMed ID: 34423535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.